Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment Diamyd Medical has entered into financing agreements with U.S. investors totaling $125 million and announced full enrollment in its Phase 3 trial.

Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment #Sweden #Stockholm #Diamyd_Medical #Phase_3_Trial #retogatein

Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion Diamyd Medical announces successful financing agreements totaling $125 million and the completion of its Phase 3 clinical trial for Type 1 diabetes.

Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion #Sweden #Stockholm #Diamyd_Medical #Phase_3_Trial #retogatein

Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis Diamyd Medical has successfully completed the clinical database for the interim analysis in its Phase 3 trial, DIAGNODE-3, assessing retogatein for type 1 diabetes treatment.

Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis #Sweden #Stockholm #Diamyd_Medical #DIAGNODE-3 #retogatein

Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S. Diamyd Medical recently announced a vital patent allowance from the USPTO for retogatein, marking progress in its diabetes treatment efforts.

Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S. #USA #Stockholm #Type_1_Diabetes #Diamyd_Medical #retogatein

Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market Diamyd Medical has received a Notice of Allowance from the USPTO for a patent on retogatein, an important immunotherapy for type 1 diabetes.

Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market #USA #Stockholm #Type_1_Diabetes #Diamyd_Medical #retogatein

Diamyd Medical's Phase 3 Diabetes Trial Readout Accelerated by FDA Guidance Diamyd Medical has received FDA approval to accelerate the readout of its Phase 3 trial for type 1 diabetes, enhancing timelines for efficacy evaluation and patient treatment options.

Diamyd Medical's Phase 3 Diabetes Trial Readout Accelerated by FDA Guidance #USA #Stockholm #Type_1_Diabetes #Diamyd_Medical #FDA_Guidance

Diamyd Medical Advances Phase 3 Diabetes Trial by Accelerating Efficacy Readout by Nine Months Diamyd Medical has successfully aligned with the FDA to accelerate the primary efficacy readout of its Phase 3 DIAGNODE-3 trial for type 1 diabetes.

Diamyd Medical Advances Phase 3 Diabetes Trial by Accelerating Efficacy Readout by Nine Months #Sweden #Stockholm #Type_1_Diabetes #Diamyd_Medical #DIAGNODE-3

Diamyd Medical's Phase 3 Diabetes Trial Achieves Key Milestone with Safety Review Completion Diamyd Medical's Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, successfully passes a critical safety review, raising hopes for early efficacy results in March 2026.

Diamyd Medical's Phase 3 Diabetes Trial Achieves Key Milestone with Safety Review Completion #Sweden #Stockholm #Type_1_Diabetes #Diamyd_Medical #DIAGNODE-3

Diamyd Medical's Phase 3 Trial for Type 1 Diabetes Advances After Final Safety Review Diamyd Medical's Phase 3 trial for Type 1 Diabetes has successfully passed a crucial safety review, positioning itself for March 2026 results.

Diamyd Medical's Phase 3 Trial for Type 1 Diabetes Advances After Final Safety Review #Sweden #Stockholm #Type_1_Diabetes #Diamyd_Medical #DIAGNODE-3

Diamyd Medical's Innovative Approach to Type 1 Diabetes Prevention and Treatment Explored Discover how Diamyd Medical is revolutionizing Type 1 Diabetes treatment with precision medicine and upcoming clinical trials aimed at prevention and curing this disease.

Diamyd Medical's Innovative Approach to Type 1 Diabetes Prevention and Treatment Explored #None #Immunotherapy #Type_1_Diabetes #Diamyd_Medical

Diamyd Medical's Promising Efforts in Preventing Type 1 Diabetes and Adult-Onset Market Expansion Diamyd Medical highlights its advancements in treating and preventing Type 1 Diabetes with a focus on adult-onset cases and upcoming Phase 3 trial results.

Diamyd Medical's Promising Efforts in Preventing Type 1 Diabetes and Adult-Onset Market Expansion #Sweden #Stockholm #Type_1_Diabetes #Diamyd_Medical #Adult-Onset_Diabetes

Diamyd Medical Expands Collaboration to Advance Type 1 Diabetes Research with $1.75 Million Support Diamyd Medical enhances its Type 1 Diabetes research efforts with $1.75 million in funding from Breakthrough T1D to push forward clinical trials for its innovative treatment.

Diamyd Medical Expands Collaboration to Advance Type 1 Diabetes Research with $1.75 Million Support #USA #Stockholm #Type_1_Diabetes #Diamyd_Medical #Breakthrough_T1D

Diamyd Medical Secures $1.75 Million for Groundbreaking Diabetes Research Diamyd Medical has announced a significant funding boost of $1.75 million from Breakthrough T1D, enhancing its Phase 3 diabetes trials.

Diamyd Medical Secures $1.75 Million for Groundbreaking Diabetes Research #Sweden #Stockholm #Type_1_Diabetes #Diamyd_Medical #Breakthrough_T1D

Diamyd Medical Reveals Promising U.S. Market Potential for Diamyd® Immunotherapy Diamyd Medical has shared an updated analysis of the promising market potential for its precision immunotherapy, Diamyd®, indicating blockbuster potential with over 60,000 potential patients in the U.S.

Diamyd Medical Reveals Promising U.S. Market Potential for Diamyd® Immunotherapy #Sweden #Immunotherapy #Stockholm #Type_1_Diabetes #Diamyd_Medical

Diamyd Medical Reveals Promising U.S. Market Potential for Diamyd® Immunotherapy Diamyd Medical has unveiled a comprehensive analysis of the market potential for Diamyd®, expecting significant demand and sales milestones in the U.S. healthcare landscape.

Diamyd Medical Reveals Promising U.S. Market Potential for Diamyd® Immunotherapy #Sweden #Immunotherapy #Stockholm #Diamyd_Medical #Diamyd®

Diamyd Medical's Major Progress Towards FDA Accelerated Approval for Diamyd® Therapy Diamyd Medical's recent meeting with the FDA brings positive news for their diamyd® therapy, aimed at treating Type 1 Diabetes, paving the way for expedited approval.

Diamyd Medical's Major Progress Towards FDA Accelerated Approval for Diamyd® Therapy #USA #FDA_Approval #Stockholm #Type_1_Diabetes #Diamyd_Medical

Diamyd Medical Progresses Towards Accelerated Approval of Diamyd® with FDA Based on Recent Meeting Insights Diamyd Medical has secured crucial progress in its journey for the accelerated approval of Diamyd® after a positive meeting with the FDA, enhancing hope for Type 1 Diabetes treatment.

Diamyd Medical Progresses Towards Accelerated Approval of Diamyd® with FDA Based on Recent Meeting Insights #Sweden #FDA #Stockholm #Type_1_Diabetes #Diamyd_Medical

Diamyd Medical Progresses Towards Accelerated Approval from FDA for Type 1 Diabetes Therapy Diamyd Medical is optimistic after aligning with the FDA on critical components for an accelerated approval process for their diabetes therapy, Diamyd®.

Diamyd Medical Progresses Towards Accelerated Approval from FDA for Type 1 Diabetes Therapy #USA #FDA_Approval #Stockholm #Type_1_Diabetes #Diamyd_Medical

Diamyd Medical's FDA Alignment Paves Way for Accelerated Approval of Innovative Diabetes Treatment Diamyd Medical has secured strategic alignment with the FDA for an accelerated approval process for Diamyd®, an innovative therapy for Type 1 Diabetes.

Diamyd Medical's FDA Alignment Paves Way for Accelerated Approval of Innovative Diabetes Treatment #Sweden #FDA_Approval #Stockholm #Type_1_Diabetes #Diamyd_Medical